title: Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection.
abstract: Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-FcγR1 affinity was significantly higher than FcγRIIIa (p<0.005) at study entry and FcγRIIb (p<0.05) or FcγRIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression.
authors.affiliation: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
authors.forename: Derseree
authors.initials: D
authors.lastname: Archary
authors.forename: Rong
authors.initials: R
authors.lastname: Rong
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Gordon
authors.forename: Saikat
authors.initials: S
authors.lastname: Boliar
authors.forename: Maphuti
authors.initials: M
authors.lastname: Madiga
authors.forename: Elin S
authors.initials: ES
authors.lastname: Gray
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Dugast
authors.forename: Tandile
authors.initials: T
authors.lastname: Hermanus
authors.forename: Philip J R
authors.initials: PJ
authors.lastname: Goulder
authors.forename: Hoosen M
authors.initials: HM
authors.lastname: Coovadia
authors.forename: Lise
authors.initials: L
authors.lastname: Werner
authors.forename: Lynn
authors.initials: L
authors.lastname: Morris
authors.forename: Galit
authors.initials: G
authors.lastname: Alter
authors.forename: Cynthia A
authors.initials: CA
authors.lastname: Derdeyn
authors.forename: Thumbi
authors.initials: T
authors.lastname: Ndung'u
mesh_terms: D000328:Adult; D057134:Antibodies, Neutralizing / Q000097:blood*; D000918:Antibody Specificity; D000940:Antigenic Variation; D018791:CD4 Lymphocyte Count; D002908:Chronic Disease; D018450:Disease Progression; D018604:Epitope Mapping; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015488:HIV Antigens / Q000235:genetics; D015658:HIV Infections / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000145:classification* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D017452:Receptors, IgG / Q000378:metabolism; D012189:Retrospective Studies; D019562:Viral Load; D055815:Young Adult
chemical_list: D057134:Antibodies, Neutralizing; D015483:HIV Antibodies; D015488:HIV Antigens; D007074:Immunoglobulin G; D017452:Receptors, IgG